We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

6 hedge funds and large institutions have $1.75M invested in Seelos Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more capital invested

Capital invested by funds: $965K → $1.75M (+$782K)

0% more funds holding

Funds holding: 6 → 6 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
6
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$1.47M
2
AAP
Ardsley Advisory Partners
Connecticut
+$36.8K

Top Sellers

Rank Fund Capital Flow
1
SCM
Sarissa Capital Management
Connecticut
-$564K
2
Franklin Resources
Franklin Resources
California
-$41K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$36.8K
4
CS
Credit Suisse
Switzerland
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$1.43M +$1.47M +40 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$70K -$36.8K -1 -33%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$70K – – –
HVC
4
Healthcare Value Capital
New Jersey
$31K – – –
AAP
5
Ardsley Advisory Partners
Connecticut
$31K +$36.8K +1 New
BlackRock
6
BlackRock
New York
$27K – – –
VF
7
Virtu Financial
New York
$15K – – –
MML Investors Services
8
MML Investors Services
Massachusetts
$13K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$12K – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$12K – – –
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Quebec, Canada
$11.3K – – –
California Public Employees Retirement System
12
California Public Employees Retirement System
California
$8K – – –
FWM
13
Frontier Wealth Management
Missouri
$6K – – –
Northern Trust
14
Northern Trust
Illinois
$5K – – –
CG
15
Colony Group
Massachusetts
$3K – – –
WP
16
WealthShield Partners
North Carolina
$3K – – –
UBS Group
17
UBS Group
Switzerland
$2K – – –
FANJ
18
Financial Architects (New Jersey)
New Jersey
$1K – – –
LTFS
19
Ladenburg Thalmann Financial Services
Florida
$1K – – –
SCM
20
Sarissa Capital Management
Connecticut
– -$564K -13 Closed
Franklin Resources
21
Franklin Resources
California
– -$41K -1 Closed
CS
22
Credit Suisse
Switzerland
– -$8K – –

SEEL Hedge Fund Activity: Q3 2018 in Review

6 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2018, worth a combined $1.75M — up 81% from $965K a quarter earlier.

Fund positioning in SEEL was balanced in Q3 2018: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.47M. The largest seller was Sarissa Capital Management, exiting entirely with an estimated $564K sold.

  • 6 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $1.75M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2018, up 81% quarter-over-quarter.
  • 2 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2018 and 2 closed out, a net change of 0 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2018 was Armistice Capital, an estimated $1.47M added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2018 was Sarissa Capital Management, an estimated $564K sold.

Based on aggregated 13F filings for Q3 2018.